Evidence map›Paper›PMID 38539225›Full record

ArticleThrombosis journal2024

Prophylaxis with enoxaparin and antithrombin III in drug-induced coagulation alterations in childhood leukemia: a retrospective experience of 20 years.

Christina Salvador, Robert Salvador, Gabriele Kropshofer, Bernhard Meister, Marie Rock, Petra Obexer, Benjamin Hetzer, Evelyn Rabensteiner, Roman Crazzolara

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thrombosis journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Christina SalvadorDepartment of Pediatrics I, Division of Hematology and Oncology, Medical University of Innsbruck, Anichstr. 35, Innsbruck, 6020, Austria. Christina.Salvador@i-med.ac.at.ORCID http://orcid.org/0000-0002-1756-7770
Robert SalvadorHTLinn, Innsbruck, Austria.
Gabriele KropshoferDepartment of Pediatrics I, Division of Hematology and Oncology, Medical University of Innsbruck, Anichstr. 35, Innsbruck, 6020, Austria.
Bernhard MeisterDepartment of Pediatrics I, Division of Hematology and Oncology, Medical University of Innsbruck, Anichstr. 35, Innsbruck, 6020, Austria.
Marie RockDepartment of Pediatrics I, Division of Hematology and Oncology, Medical University of Innsbruck, Anichstr. 35, Innsbruck, 6020, Austria.
Petra ObexerDepartment of Pediatrics II, Medical University of Innsbruck, Innsbruck, Austria.
Benjamin HetzerDepartment of Pediatrics I, Division of Hematology and Oncology, Medical University of Innsbruck, Anichstr. 35, Innsbruck, 6020, Austria.
Evelyn RabensteinerDepartment of Pediatrics I, Division of Hematology and Oncology, Medical University of Innsbruck, Anichstr. 35, Innsbruck, 6020, Austria.
Roman CrazzolaraDepartment of Pediatrics I, Division of Hematology and Oncology, Medical University of Innsbruck, Anichstr. 35, Innsbruck, 6020, Austria.
Innsbruck Medical University · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThromboembolic complications are well known in the treatment of childhood acute lymphoblastic leukemia. Over the years it has not been possible to reach a consensus on a possible prophylaxis of thromboembolic events during intensive therapy. Only the administration of enoxaparin was able to achieve evidence in the literature to date.

methodsIn this retrospective study, 173 childhood leukemia patients were treated over 20 years with a thromboembolic prophylaxis including enoxaparin and AT III during induction therapy with L-asparaginase and cortisone.

resultsWe here report the effectiveness of administration of enoxaparin and AT III in childhood leukemia, showing a strikingly low prevalence of deep vein thrombosis (2.9%). Especially in adolescent patients, a particularly great need for AT III was demonstrated.

conclusionsWe recommend thromboembolic prophylaxis with enoxaparin and AT III substitution during induction/reinduction therapy with L-asparaginase and glucocorticosteroids, especially from adolescence onwards.

Indexed as

Antithrombin IIIChildrenCoagulationEnoxaparinL-asparaginaseLeukemia

Identifiers

PMID38539225
PMCPMC10976720
OpenAlexW4393234385

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.